1	Grape	Grape	B-NP	NN	O	3	NMOD	-1
2	seed	seed	I-NP	NN	O	3	NMOD	-1
3	extract	extract	I-NP	NN	O	4	SUB	-1
4	inhibits	inhibit	B-VP	VBZ	O	0	ROOT	18	inhibits
5	angiogenesis	angiogenesis	B-NP	NN	O	4	OBJ	3	angiogenesis
6	via	via	B-PP	IN	O	4	VMOD	0
7	suppression	suppression	B-NP	NN	O	6	PMOD	18	suppression
8	of	of	B-PP	IN	O	7	NMOD	-1
9	the	the	B-NP	DT	O	16	NMOD	-1
10	vascular	vascular	I-NP	JJ	B-protein	16	NMOD	-1
11	endothelial	endothelial	I-NP	JJ	I-protein	16	NMOD	-1
12	growth	growth	I-NP	NN	I-protein	16	NMOD	0
13	factor	factor	I-NP	NN	I-protein	16	NMOD	-1
14	receptor	receptor	I-NP	NN	I-protein	16	NMOD	-1
15	signaling	signaling	I-NP	NN	O	16	NMOD	0
16	pathway	pathway	I-NP	NN	O	8	PMOD	0
17	.	.	O	.	O	4	P	-1

1	Blockade	Blockade	B-NP	NN	O	4	SUB	18	Blockade
2	of	of	B-PP	IN	O	1	NMOD	-1
3	angiogenesis	angiogenesis	B-NP	NN	O	2	PMOD	3	angiogenesis
4	is	be	B-VP	VBZ	O	0	ROOT	-1
5	an	an	B-NP	DT	O	7	NMOD	-1
6	important	important	I-NP	JJ	O	7	NMOD	0
7	approach	approach	I-NP	NN	O	4	PRD	-1
8	for	for	B-PP	IN	O	7	NMOD	-1
9	cancer	cancer	B-NP	NN	O	10	NMOD	-1
10	treatment	treatment	I-NP	NN	O	12	NMOD	19	treatment
11	and	and	I-NP	CC	O	12	NMOD	-1
12	prevention	prevention	I-NP	NN	O	8	PMOD	18	prevention
13	.	.	O	.	O	4	P	-1

1	Vascular	Vascular	B-NP	JJ	B-protein	4	NMOD	-1
2	endothelial	endothelial	I-NP	JJ	I-protein	4	NMOD	-1
3	growth	growth	I-NP	NN	I-protein	4	NMOD	0
4	factor	factor	I-NP	NN	I-protein	8	SUB	-1
5	(	(	O	(	O	7	DEP	-1
6	VEGF	VEGF	B-NP	NN	B-protein	7	DEP	-1
7	)	)	O	)	O	4	NMOD	-1
8	is	be	B-VP	VBZ	O	0	ROOT	-1
9	one	one	B-NP	CD	O	8	PRD	-1
10	of	of	B-PP	IN	O	9	NMOD	-1
11	the	the	B-NP	DT	O	14	NMOD	-1
12	most	most	I-NP	RBS	O	13	AMOD	-1
13	critical	critical	I-NP	JJ	O	14	NMOD	0
14	factors	factor	I-NP	NNS	O	10	PMOD	-1
15	that	that	B-NP	WDT	O	14	NMOD	-1
16	induce	induce	B-VP	VBP	O	15	SBAR	17	induce
17	angiogenesis	angiogenesis	B-NP	NN	O	16	OBJ	3	angiogenesis
18	and	and	O	CC	O	16	VMOD	-1
19	has	have	B-VP	VBZ	O	16	VMOD	-1
20	thus	thus	I-VP	RB	O	19	VMOD	-1
21	become	become	I-VP	VBN	O	19	VMOD	-1
22	an	an	B-NP	DT	O	24	NMOD	-1
23	attractive	attractive	I-NP	JJ	O	24	NMOD	-1
24	target	target	I-NP	NN	O	21	PRD	0
25	for	for	B-PP	IN	O	24	NMOD	-1
26	antiangiogenesis	antiangiogenesis	B-NP	NN	O	27	NMOD	3	angiogenesis
27	treatment	treatment	I-NP	NN	O	25	PMOD	18	treatment
28	.	.	O	.	O	8	P	-1

1	However	However	B-ADVP	RB	O	8	VMOD	-1
2	,	,	O	,	O	8	P	-1
3	most	most	B-NP	RBS	O	5	AMOD	-1
4	current	current	I-NP	JJ	O	5	AMOD	-1
5	anti-VEGF	anti-VEGF	I-NP	JJ	O	6	NMOD	-1
6	agents	agent	I-NP	NNS	O	8	SUB	-1
7	often	often	B-ADVP	RB	O	8	VMOD	-1
8	cause	cause	B-VP	VBP	O	0	ROOT	-1
9	some	some	B-NP	DT	O	11	NMOD	-1
10	side	side	I-NP	NN	O	11	NMOD	-1
11	effects	effect	I-NP	NNS	O	8	OBJ	0
12	when	when	B-ADVP	WRB	O	8	VMOD	-1
13	given	give	B-VP	VBN	O	12	SBAR	0
14	chronically	chronically	B-ADVP	RB	O	13	VMOD	-1
15	.	.	O	.	O	8	P	-1

1	Identification	Identification	B-NP	NN	O	10	SUB	-1
2	of	of	B-PP	IN	O	1	NMOD	-1
3	naturally	naturally	B-VP	RB	O	4	AMOD	-1
4	occurring	occur	I-VP	VBG	O	2	PMOD	-1
5	VEGF	VEGF	B-NP	NN	O	6	NMOD	-1
6	inhibitors	inhibitor	I-NP	NNS	O	4	OBJ	-1
7	derived	derive	B-VP	VBN	O	6	NMOD	0
8	from	from	B-PP	IN	O	7	VMOD	-1
9	diet	diet	B-NP	NN	O	8	PMOD	-1
10	would	would	B-VP	MD	O	0	ROOT	-1
11	be	be	I-VP	VB	O	10	VC	-1
12	one	one	B-NP	CD	O	14	NMOD	-1
13	alternative	alternative	I-NP	JJ	O	14	NMOD	-1
14	approach	approach	I-NP	NN	O	11	PRD	-1
15	with	with	B-PP	IN	O	14	NMOD	-1
16	an	an	B-NP	DT	O	17	NMOD	-1
17	advantage	advantage	I-NP	NN	O	15	PMOD	-1
18	of	of	B-PP	IN	O	17	NMOD	-1
19	known	know	B-NP	VBN	O	20	NMOD	-1
20	safety	safety	I-NP	NN	O	18	PMOD	-1
21	.	.	O	.	O	10	P	-1

1	Grape	Grape	B-NP	NN	O	3	NMOD	-1
2	seed	seed	I-NP	NN	O	3	NMOD	-1
3	extract	extract	I-NP	NN	O	12	NMOD	-1
4	(	(	O	(	O	6	DEP	-1
5	GSE	GSE	B-NP	NN	B-protein	6	DEP	-1
6	)	)	O	)	O	3	NMOD	-1
7	,	,	O	,	O	12	P	-1
8	a	a	B-NP	DT	O	12	NMOD	-1
9	widely	widely	I-NP	RB	O	10	AMOD	-1
10	used	use	I-NP	VBN	O	12	NMOD	0
11	dietary	dietary	I-NP	JJ	O	12	NMOD	-1
12	supplement	supplement	I-NP	NN	O	14	SUB	-1
13	,	,	O	,	O	12	P	-1
14	is	be	B-VP	VBZ	O	0	ROOT	-1
15	known	know	I-VP	VBN	O	14	VC	-1
16	to	to	I-VP	TO	O	17	VMOD	-1
17	have	have	I-VP	VB	O	15	VMOD	-1
18	antitumor	antitumor	B-NP	JJ	O	19	NMOD	-1
19	activity	activity	I-NP	NN	O	17	OBJ	18	activity
20	.	.	O	.	O	14	P	-1

1	In	In	B-PP	IN	O	6	VMOD	-1
2	this	this	B-NP	DT	O	3	NMOD	-1
3	study	study	I-NP	NN	O	1	PMOD	-1
4	,	,	O	,	O	6	P	-1
5	we	we	B-NP	PRP	O	6	SUB	-1
6	have	have	B-VP	VBP	O	0	ROOT	-1
7	explored	explore	I-VP	VBN	O	6	VC	-1
8	the	the	B-NP	DT	O	9	NMOD	-1
9	activity	activity	I-NP	NN	O	7	OBJ	0
10	of	of	B-PP	IN	O	9	NMOD	-1
11	GSE	GSE	B-NP	NN	B-protein	10	PMOD	-1
12	on	on	B-PP	IN	O	9	NMOD	-1
13	VEGF	VEGF	B-NP	NN	B-protein	14	NMOD	-1
14	receptor	receptor	I-NP	NN	I-protein	16	NMOD	-1
15	and	and	I-NP	CC	O	16	NMOD	-1
16	angiogenesis	angiogenesis	I-NP	NN	O	12	PMOD	3	angiogenesis
17	.	.	O	.	O	6	P	-1

1	We	We	B-NP	PRP	O	2	SUB	-1
2	found	find	B-VP	VBD	O	0	ROOT	0
3	that	that	B-SBAR	IN	O	2	VMOD	-1
4	GSE	GSE	B-NP	NN	B-protein	5	SUB	-1
5	could	could	B-VP	MD	O	3	SBAR	-1
6	directly	directly	I-VP	RB	O	7	VMOD	-1
7	inhibit	inhibit	I-VP	VB	O	5	VC	18	inhibit
8	the	the	B-NP	DT	O	10	NMOD	-1
9	kinase	kinase	I-NP	NN	O	10	NMOD	-1
10	activity	activity	I-NP	NN	O	7	OBJ	0
11	of	of	B-PP	IN	O	10	NMOD	-1
12	purified	purify	B-NP	VBN	B-protein	14	NMOD	0
13	VEGF	VEGF	I-NP	NN	I-protein	14	NMOD	-1
14	receptor	receptor	I-NP	NN	I-protein	19	NMOD	-1
15	2	2	I-NP	CD	I-protein	14	NMOD	-1
16	,	,	O	,	O	19	P	-1
17	a	a	B-NP	DT	O	19	NMOD	-1
18	novel	novel	I-NP	JJ	O	19	NMOD	-1
19	activity	activity	I-NP	NN	O	11	PMOD	0
20	of	of	B-PP	IN	O	19	NMOD	-1
21	GSE	GSE	B-NP	NN	B-protein	20	PMOD	-1
22	that	that	B-NP	WDT	O	21	NMOD	-1
23	has	have	B-VP	VBZ	O	22	SBAR	-1
24	not	not	I-VP	RB	O	23	VMOD	-1
25	been	be	I-VP	VBN	O	23	VC	-1
26	characterized	characterize	I-VP	VBN	O	25	VC	-1
27	.	.	O	.	O	2	P	-1

1	GSE	GSE	B-NP	NN	B-protein	2	SUB	-1
2	could	could	B-VP	MD	O	0	ROOT	-1
3	also	also	I-VP	RB	O	2	VMOD	-1
4	inhibit	inhibit	I-VP	VB	O	2	VC	18	inhibit
5	the	the	B-NP	DT	O	11	NMOD	-1
6	VEGF	VEGF	I-NP	NN	B-protein	11	NMOD	-1
7	receptor/mitogen-activated	receptor/mitogen-activated	I-NP	JJ	I-protein	11	NMOD	-1
8	protein	protein	I-NP	NN	I-protein	11	NMOD	-1
9	kinase-mediated	kinase-mediated	I-NP	JJ	O	11	NMOD	17	mediated
10	signaling	signaling	I-NP	NN	O	11	NMOD	0
11	pathway	pathway	I-NP	NN	O	4	OBJ	0
12	in	in	B-PP	IN	O	11	NMOD	-1
13	endothelial	endothelial	B-NP	JJ	B-cell_type	14	NMOD	-1
14	cells	cell	I-NP	NNS	I-cell_type	12	PMOD	-1
15	.	.	O	.	O	2	P	-1

1	As	As	B-PP	IN	O	6	VMOD	-1
2	a	a	B-NP	DT	O	3	NMOD	-1
3	result	result	I-NP	NN	O	1	PMOD	-1
4	,	,	O	,	O	6	P	-1
5	GSE	GSE	B-NP	NN	B-protein	6	SUB	-1
6	could	could	B-VP	MD	O	0	ROOT	-1
7	inhibit	inhibit	I-VP	VB	O	6	VC	18	inhibit
8	VEGF-induced	VEGF-induced	B-NP	JJ	O	11	NMOD	17	induced
9	endothelial	endothelial	I-NP	JJ	O	11	NMOD	-1
10	cell	cell	I-NP	NN	O	11	NMOD	-1
11	proliferation	proliferation	I-NP	NN	O	13	NMOD	1	proliferation
12	and	and	I-NP	CC	O	13	NMOD	-1
13	migration	migration	I-NP	NN	O	18	NMOD	14	migration
14	as	as	B-CONJP	RB	O	18	NMOD	-1
15	well	well	I-CONJP	RB	O	14	DEP	-1
16	as	as	I-CONJP	IN	O	14	DEP	-1
17	sprout	sprout	B-NP	NN	O	18	NMOD	-1
18	formation	formation	I-NP	NN	O	7	OBJ	2	formation
19	from	from	B-PP	IN	O	18	NMOD	-1
20	aorta	aorta	B-NP	NN	O	21	NMOD	-1
21	ring	ring	I-NP	NN	O	19	PMOD	-1
22	.	.	O	.	O	6	P	-1

1	In	In	B-NP	FW	O	2	AMOD	-1
2	vivo	vivo	I-NP	FW	O	3	NMOD	-1
3	assay	assay	I-NP	NN	O	5	SUB	-1
4	further	further	B-ADVP	RB	O	5	VMOD	-1
5	showed	show	B-VP	VBD	O	0	ROOT	-1
6	that	that	B-SBAR	IN	O	5	VMOD	-1
7	GSE	GSE	B-NP	NN	B-protein	8	SUB	-1
8	could	could	B-VP	MD	O	6	SBAR	-1
9	inhibit	inhibit	I-VP	VB	O	8	VC	18	inhibit
10	tumor	tumor	B-NP	NN	O	11	NMOD	-1
11	growth	growth	I-NP	NN	O	14	NMOD	4	growth
12	and	and	O	CC	O	14	NMOD	-1
13	tumor	tumor	B-NP	NN	O	14	NMOD	-1
14	angiogenesis	angiogenesis	I-NP	NN	O	9	OBJ	3	angiogenesis
15	of	of	B-PP	IN	O	14	NMOD	-1
16	MDA-MB-231	MDA-MB-231	B-NP	NN	B-cell_type	19	NMOD	-1
17	breast	breast	I-NP	NN	I-cell_type	19	NMOD	-1
18	cancer	cancer	I-NP	NN	I-cell_type	19	NMOD	-1
19	cells	cell	I-NP	NNS	I-cell_type	15	PMOD	-1
20	in	in	B-PP	IN	O	9	VMOD	-1
21	mice	mouse	B-NP	NNS	O	20	PMOD	-1
22	.	.	O	.	O	5	P	-1

1	Consistent	Consistent	B-ADJP	JJ	O	13	VMOD	-1
2	with	with	B-PP	IN	O	1	AMOD	-1
3	the	the	B-NP	DT	O	6	NMOD	-1
4	in	in	I-NP	FW	O	5	AMOD	-1
5	vitro	vitro	I-NP	FW	O	6	NMOD	-1
6	data	datum	I-NP	NNS	O	2	PMOD	-1
7	,	,	O	,	O	13	P	-1
8	GSE	GSE	B-NP	NN	O	9	NMOD	-1
9	treatment	treatment	I-NP	NN	O	13	SUB	19	treatment
10	of	of	B-PP	IN	O	9	NMOD	-1
11	tumor-bearing	tumor-bearing	B-NP	JJ	O	12	NMOD	-1
12	mice	mouse	I-NP	NNS	O	10	PMOD	-1
13	led	lead	B-VP	VBD	O	0	ROOT	17	led
14	to	to	B-PP	TO	O	13	VMOD	-1
15	concomitant	concomitant	B-NP	JJ	O	16	NMOD	-1
16	reduction	reduction	I-NP	NN	O	22	NMOD	18	reduction
17	of	of	B-PP	IN	O	16	NMOD	-1
18	blood	blood	B-NP	NN	O	20	NMOD	-1
19	vessel	vessel	I-NP	NN	O	20	NMOD	-1
20	density	density	I-NP	NN	O	17	PMOD	-1
21	and	and	I-NP	CC	O	22	NMOD	-1
22	phosphorylation	phosphorylation	I-NP	NN	O	14	PMOD	12	phosphorylation
23	of	of	B-PP	IN	O	22	NMOD	-1
24	mitogen-activated	mitogen-activated	B-NP	JJ	B-protein	26	NMOD	-1
25	protein	protein	I-NP	NN	I-protein	26	NMOD	-1
26	kinase	kinase	I-NP	NN	I-protein	23	PMOD	-1
27	.	.	O	.	O	13	P	-1

1	Depletion	Depletion	B-NP	NN	O	6	SUB	18	Depletion
2	of	of	B-PP	IN	O	1	NMOD	-1
3	polyphenol	polyphenol	B-NP	NN	O	2	PMOD	-1
4	with	with	B-PP	IN	O	1	NMOD	-1
5	polyvinylpyrrolidone	polyvinylpyrrolidone	B-NP	NN	O	4	PMOD	-1
6	abolished	abolish	B-VP	VBD	O	0	ROOT	18	abolished
7	the	the	B-NP	DT	O	9	NMOD	-1
8	antiangiogenic	antiangiogenic	I-NP	JJ	O	9	NMOD	3	angiogenic
9	activity	activity	I-NP	NN	O	6	OBJ	18	activity
10	of	of	B-PP	IN	O	9	NMOD	-1
11	GSE	GSE	B-NP	NN	B-protein	10	PMOD	-1
12	,	,	O	,	O	6	P	-1
13	suggesting	suggest	B-VP	VBG	O	6	VMOD	-1
14	a	a	B-NP	DT	O	16	NMOD	-1
15	water-soluble	water-soluble	I-NP	JJ	O	16	NMOD	-1
16	fraction	fraction	I-NP	NN	O	13	OBJ	-1
17	of	of	B-PP	IN	O	16	NMOD	-1
18	polyphenol	polyphenol	B-NP	NN	O	17	PMOD	-1
19	in	in	B-PP	IN	O	16	NMOD	-1
20	GSE	GSE	B-NP	NN	B-protein	19	PMOD	-1
21	is	be	B-VP	VBZ	O	6	VMOD	-1
22	responsible	responsible	B-ADJP	JJ	O	21	PRD	17	responsible
23	for	for	B-PP	IN	O	22	AMOD	-1
24	the	the	B-NP	DT	O	26	NMOD	-1
25	antiangiogenic	antiangiogenic	I-NP	JJ	O	26	NMOD	3	angiogenic
26	activity	activity	I-NP	NN	O	23	PMOD	18	activity
27	.	.	O	.	O	6	P	-1

1	Taken	Take	B-VP	VBN	O	6	VMOD	-1
2	together	together	B-ADVP	RB	O	1	VMOD	-1
3	,	,	O	,	O	6	P	-1
4	this	this	B-NP	DT	O	5	NMOD	-1
5	study	study	I-NP	NN	O	6	SUB	-1
6	indicates	indicate	B-VP	VBZ	O	0	ROOT	-1
7	that	that	B-SBAR	IN	O	6	VMOD	-1
8	GSE	GSE	B-NP	NN	B-protein	9	SUB	-1
9	is	be	B-VP	VBZ	O	7	SBAR	-1
10	a	a	B-NP	DT	O	16	NMOD	-1
11	well-tolerated	well-tolerated	I-NP	JJ	O	13	AMOD	-1
12	and	and	I-NP	CC	O	13	AMOD	-1
13	inexpensive	inexpensive	I-NP	JJ	O	16	NMOD	-1
14	natural	natural	I-NP	JJ	O	16	NMOD	-1
15	VEGF	VEGF	I-NP	NN	O	16	NMOD	-1
16	inhibitor	inhibitor	I-NP	NN	O	9	PRD	0
17	and	and	O	CC	O	9	VMOD	-1
18	could	could	B-VP	MD	O	9	VMOD	-1
19	potentially	potentially	I-VP	RB	O	18	VMOD	-1
20	be	be	I-VP	VB	O	18	VC	-1
21	useful	useful	B-ADJP	JJ	O	20	PRD	-1
22	in	in	B-PP	IN	O	21	AMOD	-1
23	cancer	cancer	B-NP	NN	O	24	NMOD	-1
24	prevention	prevention	I-NP	NN	O	26	NMOD	18	prevention
25	or	or	I-NP	CC	O	26	NMOD	-1
26	treatment	treatment	I-NP	NN	O	22	PMOD	19	treatment
27	.	.	O	.	O	6	P	-1

